Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition

Drug Development and Industrial Pharmacy

Volumn 34, Issue 8, 2008, Pages 890-902

  Miller, Dave A ^a   DiNunzio, James C ^a   Yang, Wei ^a   McGinity, James W ^a   Williams III, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Amorphous; Bioavailability; Enteric; Hot melt extrusion; In vivo; Itraconazole; Solid dispersion; Solid solution; Supersaturation

Indexed keywords

EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; ITRACONAZOLE; METHYLCELLULOSE; POVIDONE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HYDRATION; IN VIVO STUDY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT; SMALL INTESTINE ABSORPTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; ITRACONAZOLE; POLYMETHACRYLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 49449093730     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040801929273     Document Type: Article

References (45)

1. Bohme, A., Just-Nubling, G., Bergmann, L., Shah, P. M., Stille, W., & Hoelzer, D. (1996). Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother., 38, 953-961.
2. Denning, D. W. (1998). Invasive aspergillosis. Clin. Infect. Dis., 26, 781-803.
3. Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., & Catanzaro, A. (1994). NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med., 97, 135-44.
4. Fridkin, S., & Jarvis, W. (1996). Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev., 9, 499-511.
5. Gao, P., Guyton, M. E., Huang, T., Bauer, J. M., Stefanski, K. J., & Lu, Q. (2004). Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev. Ind. Pharm., 30, 221-229.
6. Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H. (2003). Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. 21, 4615-4626.
7. Grant, S. M., & Clissold, S. P. (1998). Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs, 37, 310-344.
8. Groll, A., Shah, P., Mentzel, C., Schneider, M., Just-Neubling, G., Huebling, G., & Huebner, K. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33, 23-32.
9. Gubbins, P. O., Gurley, B. J., & Bowman, J. (1998). Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J. Pharm. Biomed. Anal., 16, 1005-1012.
10. Hardin, T. C., Graybill, J. R., Fetchick, R., Woestenborghs, R., Rinaldi, M. G., & Kuhn, J. G. (1988). Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother., 32, 1310-1313.
11. Janssen, L. P. (2006 June). Sporanox (Itraconazole capsules). Prescribing Information. Beerse, Belgium: Janssen Pharmaceutica. Available from: http://www.sporanox.com.
12. Janssens, S., de Armas, H. N., Remon, J. P., & Van den Mooter, G. (2007). The use of a new hydrophilic polymer, Kollicoat IR(R), in the formulation of solid dispersions of Itraconazole. Eur. J. Pharm. Sci., 30, 288-294.
13. Jung, J.-Y., Yoo, S. D., Lee, S.-H., Kim, K.-H., Yoon, D.-S., & Lee, K.-H. (1999). Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm., 187, 209-218.
14. Lee, S., Nam, K., Kim, M. S., Jun, S. W., Park, J. S., Woo, J. S., & Hwang, S. J. (2005). Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability. Arch. Pharm. Res., 28, 866-874.
15. Lewis, R. E., Wiederhold, N. P., & Klepser, M. E. (2005). In vitro pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicro. Agents Chemother., 945-951.
16. Lin, S.-J., Schranz, J., & Tentsch, S. M. (2001). Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis., 32, 358.
17. McKinsey, D. S., Wheat, L. J., Cloud, G. A., Pierce, M., Black, J. R., Bamberger, D. M., Goldman, M., Thomas, C. J., Gutsch, H. M., Moskovitz, B., Dismukes, W. E., & Kauffman, C. A. (1999). Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency. Clin. Infect. Dis., 28, 1049.
18. Miller, D. A., Gamba, M., Sauer, D., Purvis, T. P., Clemens, N. T., & Williams III, R. O. (2007). Evaluation of the USP dissolution test method A for enteric-coated articles by planar laser-induced fluorescence. Int. J. Pharm. 330, 61-72.
19. Miller, D. A., McConville, J. T., Yang, W., Williams III, R. O., & McGinity, J. W. (2007). Hot-melt extrusion for enhanced delivery of drug particles. J. Pharm. Sci., 96, 361-376.
20. Mouy, R., Veber, F., Blanche, S., Donadieu, J., Brauner, R., Levron, J. C., Griscelli, C., & Fischer, A. (1994). Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J. Pediatr., 125(Dec), 998-1003.
21. Myoken, Y., Sugata, T., Kyo, T., Fujihara, M., & Mikami, Y. (2002). Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J. Periodontol., 73, 33-38.
22. Okimoto, K., Miyake, M., Ibuki, R., Yasumura, M., Ohnishi, N., & Nakai, T. (1997). Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose. Int. J. Pharm. 159, 85-93.
23. Overhoff, K. A., Moreno, A., Miller, D. A., Johnston, K. P., & Williams III, R. O. (2007). Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing. Int. J. Pharm., 336, 122-132.
24. Peeters, J., Neeskens, P., Tollenaere, J. P., Van Remoortere, P., & Brewster, M. (2002). Characterization of the interaction of 2-hydroxypropyl-B- cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci., 91, 1414-1422.
25. Petereit, H.-U., & Weisbrod, W. (1999). Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers. Eur. J. Pharm. Biopharm., 47, 15-25.
26. Rambali, B., Verreck, G., Baert, L., & Massart, D. L. (2003). Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm., 29, 641-652.
27. Selik, R., Karon, J., & Ward, J. (1997). Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J. Infect. Dis., 176, 632-636.
28. Shin-Etsu. (2007). Certificate of Analysis - Hypromellose Phthalate, NF HP-55. Shin-Etsu Chemical Co Tokoyo, Japan.
29. Six, K., Daems, T., de Hoon, J., Van Hecken, A., Depre, M., Bouche, M.-P., Prinsen, P., Verreck, G., Peeters, J., Brewster, M. E., & Van den Mooter, G. (2005). Clinical study of solid dispersions of itraconazole prepared by hotstage extrusion. Eur. J. Pharm. Sci., 24, 179-186.
30. Six, K., Leuner, C., Dressman, J., Verreck, G., Peeters, J., Blaton, N., Augustijns, P., Kinget, R., & Van den Mooter, G. (2002). Thermal properties of hot-stage extrudates of itraconazole and eudragit E100. Phase separation and polymorphism. J. Therm. Anal. Calorim., 68, 591-601.
31. g with that of structural analogues using MTDSC. Int. J. Pharm. 213, 163-173.
32. Six, K., Verreck, G., Peeters, J., Binnemans, K., Berghmans, H., Augustijns, P., Kinget, R., & Van den Mooter, G. (2001). Investigation of thermal properties of glassy itraconazole: Identification of a monotropic mesophase. Thermochimica. Acta., 376, 175-181.
33. Six, K., Verreck, G., Peeters, J., Brewster, M. E., & Van den Mooter, G. (2004). Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J. Pharm. Sci. 93, 124-131.
34. Suzuki, H., & Sunada, H. (1998). Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers. Chem. Pharm. Bull., 46, 482-487.
35. Van den Mooter, G., Weuts, I., De Ridder, T., & Blaton, N. (2006). Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int. J. Pharm. 316:1-6.
36. Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., & Williams III, R. O. (2006). Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm., 63, 95-102.
37. Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., & Brewster, M. E. (2003). Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm. Res. 20, 810-817.
38. Verreck, G., Six, K., Van den Mooter, G., Baert, L., Peeters, J., & Brewster, M. E. (2003). Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion - Part I. Int. J. Pharm. 251, 165-174.
39. Wang, X., Michoel, A., & Van den Mooter, G. (2005). Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm., 303, 54-61.
40. Yamashita, K., Nakate, T., Okimoto, K., Ohike, A., Tokunaga, Y., Ibuki, R., Higaki, K., & Kimura, T. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm., 267, 79-91.
41. Yamazaki, T., Kume, H., Yamashita, E., Murase, S., & Arisawa, M. (1997). Epidemiology of visceral mycoses: Analysis on data in annual of the pathological autopsy cases in Japan [abstract P-117]. In: 13th Congress of the International Society for Human and Animal Mycology. Parma, Italy.
42. Ye, G., Wang, S., Heng, P. W. S., Chen, L., & Wang, C. (2007). Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int. J. Pharm., 337, 80-87.
43. Yokoi, Y., Yonemochi, E., & Terada, K. (2005). Effects of sugar ester and hydroxypropyl methylcellulose on the physicochemical stability of amorphous cefditoren pivoxil in aqueous suspension. Int. J. Pharm., 290, 91-99.
44. Yoo, S. D., Lee, S.-H., Kang, E., Jun, H., Jung, J.-Y., Park, J. W., & Lee, K.-H. (2000). Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles. Drug Dev. Ind. Pharm., 27-34.
45. Zhou, H., Goldman, M., Wu, J., Woestenborghs, R., Hassell, A. E., Lee, P., Baruch, A., Pesco-Koplowitz, L., Borum, J., & Wheat, L. J. (1998). A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J. Clin. Pharmacol., 38, 593-602.